Lowest Price Guaranteed
Pages
221
Last Updated
August 2026
View Count
19555
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Historical Evolution of Bacteriophages
6.3. Biology of Bacteriophages
6.4. Introduction to Bacteriophage Therapy
6.5. Applications of Bacteriophage Therapy
6.6. Advantages of Bacteriophage Therapy
6.7. Limitations of Bacteriophage Therapy
6.8. Conclusion
7. BACTERIOPHAGE THERAPY: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Bacteriophage Therapy: Drug Pipeline
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Therapeutic Area
7.2.3. Analysis by Phase of Development and Therapeutic Area
7.2.4. Analysis by Targeted Bacterial Strain
7.2.5. Analysis by Target Disease Indication
7.2.6. Analysis by Type of Therapy
7.2.7. Analysis by Route of Administration
7.3. Information on Bacteriophage Related Technologies
8. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE
8.1. Chapter Overview
8.2. Bacteriophage Therapeutics: List of Developers
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Company Size and Location of Headquarters
8.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics
9. COMPANY AND DRUG PROFILES
9.1. Chapter Overview
9.2. Adaptive Phage Therapeutics*
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Pipeline Overview
9.2.4. Recent Developments and Future Outlook
* Similar details are presented for other companies mentioned below (based on information in the public domain)
9.3. ContraFect
9.4. Eliava BioPreparations
9.5. Micreos
9.6. NPO Microgen
9.7. Phagelux
9.8. Pherecydes Pharma
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bacteriophage Therapy Market: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.3. Analysis by Trial Status
10.3.4. Analysis by Trial Phase and Enrolled Patient Population
10.3.5. Analysis by Study Design
10.3.6. Analysis by Type of Sponsor / Collaborator
10.3.7. Most Active Players: Analysis by Number of Registered Trials
10.3.8. Regional Analysis
10.3.8.1. Analysis by Number of Registered Trials
10.3.8.2. Analysis by Enrolled Patient Population
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bacteriophage Therapy: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
11.3.4. Analysis by Geography
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Type of Applicant
11.3.7. Leading Players: Analysis by Number of Patents
11.4. Bacteriophage Therapy: Patent Benchmarking
11.4.1. Analysis by Patent Characteristics
11.5. Bacteriophage Therapy: Patent Valuation
11.6. List of Leading Patents
12. PUBLICATION BENCHMARKING ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.2.1. Analysis by Year of Publication
12.2.2. Analysis by Type of Article
12.2.3. Analysis by Popular Keywords
12.2.4. Popular Publishers: Analysis by Number of Publications
12.2.5. Popular Journals: Analysis by Number of Publications
12.2.6. Popular Journals: Analysis by Journal Impact Factor
12.2.7. Publications: Timeline Analysis
12.3. Publication Benchmarking
13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Bacteriophage Therapy: Academic Grant Analysis
13.3.1. Analysis by Year of Grant Award
13.3.2. Analysis by Amount Awarded
13.3.3. Analysis by Administering Institute Center
13.3.4. Analysis by Support Period
13.3.5. Analysis by Funding Institute Center and Support Period
13.3.6. Analysis by Type of Grant Application
13.3.7. Analysis by Purpose of Grant Award
13.3.8. Analysis by Activity Code
13.3.9. Word Cloud Analysis: Emerging Focus Areas
13.3.10. Analysis by Study Section Involved
13.3.11. Popular NIH Departments: Analysis by Number of Grants
13.3.12. Analysis by Type of Recipient Organization
13.3.13. Prominent Program Officers: Analysis by Number of Grants
13.3.14. Popular Recipient Organizations: Analysis by Number of Grants
13.3.15. Regional Distribution of Recipient Organizations
14. FUNDING AND INVESTMENTS ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Bacteriophage Therapy Market: List of Funding and Investments
14.3.1. Analysis by Year of Investment
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
14.3.5. Investors Analysis
14.3.6. Regional Distribution by Amount Invested
14.4. Concluding Remarks
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year of Partnership and Type of Partner
15.3.4. Analysis by Therapeutic Area
15.3.5. Analysis by Application Area
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.7.1. Intercontinental and Intracontinental Agreements
16. START-UP HEALTH INDEXING
16.1. Chapter Overview
16.2. Bacteriophage Therapeutics Developers: Start-ups
16.2.1. Analysis by Location of Headquarters
16.3. Benchmarking of Start-ups
16.3.1. Analysis by Pipeline Strength
16.3.2. Analysis by Pipeline Maturity
16.3.3. Analysis by Indication Diversity
16.3.4. Analysis by Number of Patents
16.3.5. Analysis by Funding Amount
16.3.6. Analysis by Partnership Activity
16.3.7. Start-ups Health Indexing: Roots Analysis Perspective
17. GLOBAL BACTERIOPHAGE THERAPY MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Roots Analysis Perspective on Market Growth
17.5. Scenario Analysis
17.5.1. Conservative Scenario
17.5.2. Optimistic Scenario
17.6. Key Market Segmentations
18. BACTERIOPHAGE THERAPY MARKET, BY TARGET INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Bacteriophage Therapy Market: Distribution by Target Indication
18.3.1. Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.2. Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.3. Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.4. Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.5. Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.6. Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. BACTERIOPHAGE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Bacteriophage Therapy Market: Distribution by Route of Administration
19.3.1. Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.2. Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.3. Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.4. Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. BACTERIOPHAGE THERAPY MARKET, BY TARGETED BACTERIA
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Bacteriophage Therapy Market: Distribution by Targeted Bacteria
20.3.1. Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.2. Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.3. Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.4. Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.5. Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.6. Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. BACTERIOPHAGE THERAPY MARKET, BY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Bacteriophage Therapy Market: Distribution by Geographical Regions
21.3.1. Bacteriophage Therapy Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.2. Bacteriophage Therapy Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.3. Bacteriophage Therapy Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.4. Bacteriophage Therapy Market in Rest of the World: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.4. Market Dynamics Assessment
21.4.1. Penetration-Growth (P-G) Matrix
21.5. Data Triangulation and Validation
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Company A
23.2.1. Company Overview
23.2.2. Interview Transcript: Chief Executive Officer
23.3. Company B
23.3.1. Company Overview
23.3.2. Interview Transcript: Senior Director, Head of Data-Science
23.4. Company C
23.4.1. Company Overview
23.4.2. Interview Transcript: Project Leader
23.5. Independent Consultant
23.5.1. Interview Transcript: Scientific Researcher
23.6. Company D
23.6.1. Company Overview
23.6.2. Interview Transcript: Founder and Chief Executive Officer
23.7. Company E
23.7.1. Company Overview
23.7.2. Interview Transcript: Co-Founder and Chief Executive Officer
23.8. Company F
23.8.1. Company Overview
23.8.2. Interview Transcript: Chief Financial Officer
23.9. Company G
23.9.1. Company Overview
23.9.2. Interview Transcript: Chief Scientific Officer
23.10. Company H
23.10.1. Company Overview
23.10.2. Interview Transcript: Co-Founder
23.11. Company I
23.11.1. Company Overview
23.11.2. Interview Transcript: Staff Scientist & Principal Investigator
23.12. Company J
23.12.1. Company Overview
23.12.2. Interview Transcript: Production Specialist
23.13. Company K
23.13.1. Company Overview
23.13.2. Interview Transcript: Professor of Medicine
23.14. Independent Researcher
23.14.1. Interview Transcript: Scientific Researcher
23.15. Independent Researcher
23.15.1. Interview Transcript: Scientific Researcher
24. APPENDIX I: TABULATED DATA
25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 History Timeline of Bacteriophage
Figure 6.2 Bacteriophage Replication Cycle
Figure 6.3 Advantages of Bacteriophage Therapy
Figure 6.4 Limitations of Bacteriophage Therapy
Figure 7.1 Bacteriophage Therapy: Distribution by Phase of Development
Figure 7.2 Bacteriophage Therapy: Distribution by Therapeutic Area
Figure 7.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
Figure 7.4 Bacteriophage Therapeutics: Distribution by Targeted Bacterial Strain
Figure 7.5 Bacteriophage Therapeutics: Distribution by Target Disease Indication
Figure 7.6 Bacteriophage Therapeutics: Distribution by Type of Therapy
Figure 7.7 Bacteriophage Therapeutics: Distribution by Route of Administration
Figure 8.1 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
Figure 8.2 Bacteriophage Therapeutics Developers: Distribution by Company Size
Figure 8.3 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
Figure 8.4 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Figure 8.5 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
Figure 10.1 Clinical Trial Analysis: Scope and Methodology
Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
Figure 10.10 Geographical Analysis: Distribution by Number of Registered Trials
Figure 10.11 Geographical Analysis: Distribution by Enrolled Patient Population
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 11.4 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
Figure 11.5 Patent Analysis: Distribution by Geography
Figure 11.6 Patent Analysis: Distribution by CPC Symbols
Figure 11.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 11.11 Patent Analysis: Distribution by Patent Age
Figure 11.12 Patent Valuation Analysis
Figure 12.1 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
Figure 12.2 Publication Benchmarking Analysis: Distribution by Type of Article
Figure 12.3 Publication Benchmarking Analysis: Distribution by Popular Keywords
Figure 12.4 Popular Publishers: Distribution by Number of Publications
Figure 12.5 Popular Journals: Distribution by Number of Publications
Figure 12.6 Popular Journals: Distribution by Journal Impact Factor
Figure 12.7 Timeline Analysis: Distribution by Article Type and Average Time to Publish
Figure 12.8 Timeline Analysis: Distribution by Journal Impact Factor and Average Time to Publish
Figure 12.9 Timeline Analysis: Distribution by Type of Article and Maximum Time to Publish
Figure 12.10 Timeline Analysis: Distribution by Journal Impact Factor and Maximum Time to Publish
Figure 12.11 Publication Benchmarking
Figure 13.1 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
Figure 13.2 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
Figure 13.3 Grant Analysis: Distribution by Administering Institute Center
Figure 13.4 Grant Analysis: Distribution by Support Period
Figure 13.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 13.6 Grant Analysis: Distribution by Type of Grant Application
Figure 13.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 13.8 Grant Analysis: Distribution by Activity Code
Figure 13.9 Word Cloud: Emerging Focus Areas
Figure 13.10 Grant Analysis: Distribution by Study Section Involved
Figure 13.11 Popular NIH Departments: Distribution by Number of Grants
Figure 13.12 Grant Analysis: Distribution by Types of Recipient Organization
Figure 13.13 Most Prominent Program Officers: Distribution by Number of Grants
Figure 13.14 Popular Recipient Organization: Distribution by Number of Grants
Figure 13.15 Grant Analysis: Regional Distribution of Recipient Organization
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
Figure 14.4 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
Figure 14.5 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
Figure 14.6 Most Active Investors: Distribution by Number of Instances
Figure 14.7 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
Figure 15.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.6 Partnerships and Collaborations: Distribution by Application Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships and Collaborations: Regional Distribution
Figure 15.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 16.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 16.2 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 16.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 16.4 Startup-Health Indexing: Distribution by Indication Diversity
Figure 16.5 Startup-Health Indexing: Distribution by Number of Patents
Figure 16.6 Startup-Health Indexing: Distribution by Funding Amount
Figure 16.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 16.8 Start-up Health Indexing: Leading Companies
Figure 17.1 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 17.2 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Figure 17.3 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Figure 17.4 Global Bacteriophage Therapy Market: Distribution by Target Indication
Figure 18.1 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.2 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million) Figure 18.3 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.4 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.5 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 18.6 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.1 Global Bacteriophage Therapy Market: Distribution by Route of Administration
Figure 19.2 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.3 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.4 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 19.5 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.1 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
Figure 20.2 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.3 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.4 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.5 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.6 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 20.7 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.1 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
Figure 21.2 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.3 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.4 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.5 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 22.1 Concluding Remarks: Market Landscape
Figure 22.2 Concluding Remarks: Clinical Trial Analysis
Figure 22.3 Concluding Remarks: Patent Analysis
Figure 22.4 Concluding Remarks: Publication Benchmarking Analysis
Figure 22.5 Concluding Remarks: Academic Grants Analysis
Figure 22.6 Concluding Remarks: Funding and Investment Analysis
Figure 22.7 Concluding Remarks: Partnerships and Collaborations
Figure 22.8 Concluding Remarks: Start-up Health Indexing
Figure 22.9 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 7.1 Bacteriophage Therapeutics: Information on Developer, Phase of Development, Bacterial Target, Target Disease Indication, Therapeutic Area
Table 7.2 Bacteriophage Therapeutics: Information on Type of Therapy and Route of Administration
Table 7.3 Bacteriophage Therapeutics: Information on Bacteriophage Related Technologies
Table 8.1 Bacteriophage Therapeutics: List of Developers
Table 9.1 Eliava BioPreparations: Company Overview
Table 9.2 Eliava BioPreparations: Pipeline Overview
Table 9.3 Micreos: Company Overview
Table 9.4 Micreos: Pipeline Overview
Table 9.5 NPO Microgen: Company Overview
Table 9.6 NPO Microgen: Pipeline Overview
Table 9.7 ContraFect: Company Overview
Table 9.8 ContraFect: Pipeline Overview
Table 9.9 Adaptive Phage Therapeutics: Company Overview
Table 9.10 Adaptive Phage Therapeutics: Pipeline Overview
Table 9.11 Phagelux: Company Overview
Table 9.12 Phagelux: Pipeline Overview
Table 9.13 Pherecydes Pharma: Company Overview
Table 9.14 Pherecydes Pharma: Pipeline Overview
Table 11.1 List of Top CPC Sections
Table 11.2 List of Top CPC Symbols
Table 11.3 List of Top CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 12.1 Publication Benchmarking: List of Top 50 Publications
Table 14.1 Bacteriophage Therapy: List of Funding and Investments, Since 2017
Table 14.2 Funding and Investment Analysis: Summary of Investment
Table 15.1 Bacteriophage Therapy: List of Partnerships and Collaborations, Since 2017
Table 24.1 Bacteriophage Therapy: Distribution by Phase of Development
Table 24.2 Bacteriophage Therapy: Distribution by Therapeutic Area
Table 24.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
Table 24.4 Bacteriophage Therapy: Distribution by Targeted Bacterial Strain
Table 24.5 Bacteriophage Therapy: Distribution by Target Disease Indication
Table 24.6 Bacteriophage Therapy: Distribution by Type of Therapy
Table 24.7 Bacteriophage Therapy: Distribution by Route of Administration
Table 24.8 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
Table 24.9 Bacteriophage Therapeutics Developers: Distribution by Company Size
Table 24.10 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
Table 24.11 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Table 24.12 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
Table 24.13 Clinical Trial Analysis: Scope and Methodology
Table 24.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
Table 24.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
Table 24.16 Clinical Trial Analysis: Distribution by Trial Status
Table 24.17 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Table 24.18 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 24.19 Clinical Trial Analysis: Distribution by Study Design
Table 24.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 24.21 Most Active Players: Distribution by Number of Registered Trials
Table 24.22 Geographical Analysis: Distribution by Number of Registered Trials
Table 24.23 Geographical Analysis: Distribution by Enrolled Patient Population
Table 24.24 Patent Analysis: Distribution by Type of Patent
Table 24.25 Patent Analysis: Cumulative Distribution by Publication Year
Table 24.26 Patent Analysis: Cumulative Distribution by Patent Application Year
Table 24.27 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
Table 24.28 Patent Analysis: Distribution by Geography
Table 24.29 Patent Analysis: Distribution by CPC Symbols
Table 24.30 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 24.31 Leading Industry Players: Distribution by Number of Patents
Table 24.32 Leading Non-Industry Players: Distribution by Number of Patents
Table 24.33 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 24.34 Patent Analysis: Distribution by Patent Age
Table 24.35 Patent Valuation Analysis
Table 24.36 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
Table 24.37 Publication Benchmarking Analysis: Distribution by Type of Article
Table 24.38 Publication Benchmarking Analysis: Distribution by Popular Keywords
Table 24.39 Popular Publishers: Distribution by Number of Publications
Table 24.40 Popular Journals: Distribution by Number of Publications
Table 24.41 Popular Journals: Distribution by Journal Impact Factor
Table 24.42 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
Table 24.43 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
Table 24.44 Grant Analysis: Distribution by Administering Institute Center
Table 24.45 Grant Analysis: Distribution by Support Period
Table 24.46 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 24.47 Grant Analysis: Distribution by Type of Grant Application
Table 24.48 Grant Analysis: Distribution by Purpose of Grant Award
Table 24.49 Grant Analysis: Distribution by Activity Code
Table 24.50 Grant Analysis: Distribution by Study Section Involved
Table 24.51 Popular NIH Departments: Distribution by Number of Grants
Table 24.52 Grant Analysis: Distribution by Types of Recipient Organization
Table 24.53 Most Prominent Program Officers: Distribution by Number of Grants
Table 24.54 Popular Recipient Organization: Distribution by Number of Grants
Table 24.55 Grant Analysis: Regional Distribution of Recipient Organization
Table 24.56 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
Table 24.57 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
Table 24.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
Table 24.59 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
Table 24.60 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
Table 24.61 Most Active Investors: Distribution by Number of Instances
Table 24.62 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
Table 24.63 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
Table 24.64 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
Table 24.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
Table 24.67 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 24.68 Partnerships and Collaborations: Distribution by Application Area
Table 24.69 Most Active Players: Distribution by Number of Partnerships
Table 24.70 Partnerships and Collaborations: Regional Distribution
Table 24.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.72 Startup-Health Indexing: Distribution by Location of Headquarters
Table 24.73 Startup-Health Indexing: Distribution by Pipeline Strength
Table 24.74 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 24.75 Startup-Health Indexing: Distribution by Indication Diversity
Table 24.76 Startup-Health Indexing: Distribution by Number of Patents
Table 24.77 Startup-Health Indexing: Distribution by Funding Amount
Table 24.78 Start-up Health Indexing: Roots Analysis Perspective
Table 24.79 Start-up Health Indexing: Leading Companies
Table 24.80 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 24.81 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Table 24.82 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Table 24.83 Global Bacteriophage Therapy Market: Distribution by Target Indication
Table 24.84 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.85 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.86 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.87 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.88 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.89 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.90 Global Bacteriophage Therapy Market: Distribution by Route of Administration
Table 24.91 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.92 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.93 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.94 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.95 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
Table 24.96 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.97 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.98 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.99 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.100 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.101 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.102 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
Table 24.103 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.104 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.105 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 24.106 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)